Braveheart Bio (BRVE)
Developing BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy.
Braveheart Bio CFO Acquires 27,777 Shares for $500,000. Is This a Signal BRVE IPO Is a Success?
The transaction involved 27,777 shares acquired for ~$500,000 on August 7, 2026. The acquisition increased the total equity position by 5%, resulting in a 0.87% ownership stake.
Braveheart Bio Chairman Chris Viehbacher Buys $1.5M Shares at IPO. What Does This Mean for Investors?
The transaction involved 83,333 shares with an estimated value of ~$1.5 million as of the August 7, 2026 market close. Director Viehbacher increased his direct equity holdings by 16% through this acquisition.
Braveheart Bio CEO Travis Murdoch Buys 83,333 Shares for $1.5 Million. Is This a Buy Signal for Investors?
Murdoch exercised options at $18 per share, increasing his total beneficial ownership to ~8 million shares valued at $161 million, representing a 13% stake.
Braveheart Bio (NASDAQ:BRVE) Director Purchases $999,990.00 in Stock
Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) Director David Charles Lubner purchased 55,555 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $18.00 per share, with a total value of $999,990.00. Following the acquisition, the director directly owned 55,555 shares in the company,
Braveheart Bio (NASDAQ:BRVE) CFO Buys $499,986.00 in Stock
Braveheart Bio, Inc. (NASDAQ: BRVE - Get Free Report) CFO James Paul Rickey bought 27,777 shares of the company's stock in a transaction on Friday, August 7th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $499,986.00. Following the completion of the transaction, the chief financial officer owned
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the closing of its upsized initial public offering of an aggregate of 24,437,500 shares of its common stock at an initial public offering price of $18.00 per share, including the full exercise by the underwriters of their option to purchase 3,187,500 additional shares. All shares of common stock were offered by Braveheart Bio.
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026 under the ticker symbol “BRVE.” The offering is expected to close on August 7, 2026, subject to the satisfaction of customary closing conditions. All shares of common stock are being offered by Braveheart Bio.
Braveheart Bio Readies $300 Million IPO Plan
Braveheart Bio is targeting a $300 million IPO to advance BHB-1893, a promising HCM treatment. BRVE's candidate showed an 86% complete response rate in Phase 2 Chinese trials; Phase 3 trials are planned for 2026–2027. Strong management, top-tier investor backing (including Fidelity's $75 million indication), and substantial de-risking support the premium $775 million proposed enterprise value.
